Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Atomo Diagnostics Limited is a medical device company. Its Rapid Diagnostic Test devices are used both by healthcare professionals and by consumers to screen for a range of diseases and medical conditions
|26 Oct 2021||$0.32||$-0.03||-8.70%||1,680,494||$0.35||$0.36||$0.31|
|25 Oct 2021||$0.35||$-0.02||-5.56%||605,462||$0.36||$0.36||$0.34|
|22 Oct 2021||$0.36||$0.02||5.88%||1,439,191||$0.34||$0.37||$0.34|
|21 Oct 2021||$0.34||$0.00||0.00%||299,411||$0.35||$0.35||$0.34|
|20 Oct 2021||$0.35||$0.00||0.00%||519,483||$0.34||$0.35||$0.34|
|19 Oct 2021||$0.34||$-0.01||-2.86%||1,339,989||$0.36||$0.36||$0.34|
|18 Oct 2021||$0.35||$-0.01||-2.78%||1,355,593||$0.36||$0.37||$0.35|
|15 Oct 2021||$0.36||$0.02||5.88%||3,889,748||$0.35||$0.37||$0.35|
|14 Oct 2021||$0.34||$0.00||0.00%||1,243,219||$0.35||$0.35||$0.34|
|13 Oct 2021||$0.35||$0.00||0.00%||403,559||$0.34||$0.35||$0.34|
|12 Oct 2021||$0.35||$0.00||0.00%||477,823||$0.35||$0.35||$0.34|
|11 Oct 2021||$0.35||$-0.01||-2.82%||1,266,220||$0.36||$0.36||$0.34|
|08 Oct 2021||$0.36||$0.04||12.50%||3,039,424||$0.33||$0.36||$0.33|
|07 Oct 2021||$0.32||$-0.01||-3.03%||2,458,291||$0.34||$0.34||$0.32|
|06 Oct 2021||$0.33||$0.03||10.00%||2,301,245||$0.31||$0.34||$0.31|
|05 Oct 2021||$0.30||$-0.04||-11.76%||3,613,434||$0.35||$0.35||$0.30|
|04 Oct 2021||$0.34||$0.01||2.99%||338,143||$0.34||$0.34||$0.34|
|01 Oct 2021||$0.34||$-0.02||-5.63%||1,365,314||$0.36||$0.36||$0.34|
|30 Sep 2021||$0.36||$-0.01||-2.78%||1,303,624||$0.37||$0.37||$0.35|
|29 Sep 2021||$0.36||$0.01||2.82%||3,584,532||$0.36||$0.37||$0.34|
|28 Sep 2021||$0.36||$0.05||16.39%||6,941,116||$0.30||$0.36||$0.30|
|09 Apr 2021||Curt LaBelle||Exercise||240||$37,500||
Exercise of options.
|09 Apr 2021||Curt LaBelle||Buy||240||$37,500||
Exercise of options.
|09 Apr 2021||Curt LaBelle||Exercise||960||$150,000||
Exercise of options.
|09 Apr 2021||Curt LaBelle||Buy||960||$150,000||
Exercise of options.
|Dr Paul Alexander Kasian||Non-Executive Director||
Dr Kasian is an experienced executive director in both domestic and international companies in senior leadership, strategy, investment and risk roles. His other roles have included Chief Investment Officer and Head of Global Financials at HSBC Asset Management, Founding Director of Accordius and Founding Director of Wallara Asset Management. Previously he served as a Non-Executive Director, then Chairman and CEO of Genetic Technologies Limited (appointed 12 December 2013 and resigned 23 September 2019). Dr Kasian is the Chair of the Risk Committee.
|Ms Constance (Connie) Bernadette Carnabuci||Non-Executive Director||Feb 2020||
Ms Carnabuci has over 30 years of experience advising intellectual property and technology businesses in Australia and across Asia on commercial, corporate and regulatory matters. Ms Carnabuci holds an executive role as the General Counsel of the Australian Broadcasting Corporation. She is a professional Non-Executive Director and currently serves on the Board and the Remuneration Committee of OFX. Ms Carnabuci is a former partner of Mallesons Stephen Jacques and Freshfields Bruckhaus Deringer. She is a member of the Business Advisory Council of the UNSW Business School. She serves as the Vice President of the Cranbrook School Parents Association. She was the Chair of the NFP, Kids Giving Back, from 2015 to 2018.
|Mr John Perry Keith||Non-Executive ChairmanNon-Executive Director||Dec 2011||
Mr Keith is a Managing Director of BNP Paribas, establishing and leading its financial institutions coverage team. Prior to joining BNP Paribas in 2011, Mr Keith held country management and senior business and coverage positions for Nomura Securities in Sydney and Hong Kong. His career comprises working with supranational, sovereign and institutional clients across all areas of investment and institutional banking. He has also served on the boards of ASIA Limited, Calliva Limited, Room to Read Australia Foundation and Ascham Foundation. He is also the member of Risk committee.
|Mr John Michael Kelly||FounderChief Executive OfficerManaging Director||Apr 2010||
Mr Kelly was into developing and commercialising medical devices for more than 20 years to enhance usability and performance, having started with CR Bard in Europe developing Class III implantable cardiology products. Prior to co-founding Atomo in 2010, Mr Kelly acted as the Chief Operating Officer (COO) of Unilife Corporation, which was previously an ASX-listed company (ASX:UNS) and subsequent to his departure, a Nasdaq listed company (NASDAQ:UNIS). At Unilife Corporation, he led the global operations team from 2005 to 2008, developing 'Unifill'. Prior to joining Unilife in 2005, Mr Kelly spent five years at ResMed where he led the New Product Implementation Group and managed the development of Mirage Swift and Activa mask systems.
|Dr Curt Harold LaBelle||Non-Executive Director||Oct 2016||
Dr LaBelle has been involved in the healthcare industry for 20 years, both operationally and as an investor. Dr LaBelle is President at the Global Health Investment Fund (GHIF). He also serves as a director on the boards of Alydia Health, Evenovia and Atticus Medical. Prior to joining GHIF, Dr LaBelle was Managing Director at Tullis Health Investors and Vice President at Investor Growth Capital. He is a former chairman of Impulse Monitoring (acquired by Nuvasive), Exagen Inc. (NASDAQ:XGN) and a former director of Sirion Therapeutics (products acquired by Alcon and Bausch), SafeOp Surgical (acquired by AlphaTec) and KAI Pharmaceuticals (acquired by Amgen). Dr LaBelle is also the member of Risk committee.
|Ms Deborah Neff||Non-Executive Director||Sep 2021||
Ms Neff has experience in building businesses and product commercialization in life sciences industry. Currently, she is advising several early-stage companies developing innovative technology to improve patient care. Most recently, she was the CEO of, Evanostics, LLC, a development stage company focused on systems for applications in point-of-care diagnostic testing in forensic and clinical toxicology. Prior to that, she was the Chief Operating Officer at Complete Genomics Inc., a life sciences company in whole genome and exome sequencing. Deborah continues as the principal of a privately held consulting company, DJN Consulting, LLC. that she formed in 2013. Prior to Complete Genomics, Deborah served as the Chief Operating Officer of Pathwork Diagnostics, Inc. and previously as CEO of Predicant Biosciences Inc. Deborah served as the global president of BD Biosciences, a major business segment of Becton Dickinson and Company until 2003. Her work experience at BD Biosciences over 15 years included various management positions including general manager, vice president and director of several business areas. Deborah's work in life sciences has included the areas of cancer diagnostics, immunocytometry and genomics, having establishing a certified clinical laboratory, guiding a molecular diagnostic test through the FDA clearance process, securing reimbursement pathways, and building commercial pipelines. Deborah served as a board member and executive management advisor for Galt Inc. and Vortex Biosciences Inc, and served on the board of BioRad, Inc. She is a former board member of Advanced Medical Optics, Inc. and ForteBio Corporation Inc., boards, which were acquired by Abbott Laboratories and Pall Corporation respectively. Deborah is an Executive Trustee of the UC Davis Foundation Board and Chairs the Global Campaign Leadership Committee. She also chairs the College of Biological Sciences Dean's Leadership Council at the University. Deborah also completed executive programs in marketing, finance, operations, and management at UCLA, Wharton, Stanford, and Harvard business schools.
|Ms Gillian Maria Nairn||Company Secretary||
|Fabio Baglioni||Chief Commercial Officer||
|William Souter||Chief Financial Officer||
|Mark Smith||Chief Operating Officer||
|Gillian Maria Nairn||Company Secretary||
|Dalraida Holdings Pty Limited||66,160,000||11.79%|
|Global Health Investment Fund I Llc||63,851,280||11.38%|
|Walker Group Holdings Pty Ltd||46,660,718||8.32%|
|National Nominees Limited||32,478,361||5.79%|
|J P Morgan Nominees Australia Pty Limited||18,556,834||3.31%|
|HSBC Custody Nominees (Australia) Limited||17,624,130||3.14%|
|Blueflag Holdings Pty Ltd||13,760,000||2.45%|
|Grand Challenges Canada||11,390,824||2.03%|
|Liverbird Pty Ltd||9,731,653||1.73%|
|Sokolov Pty Ltd||9,202,181||1.64%|
|I D E Pty Ltd <Atf Ide Trust>||9,032,248||1.61%|
|Mark Andrew Smith||7,790,224||1.39%|
|John Michael Kelly||7,370,248||1.31%|
|Leo James Lynch & Judith Anne Beswick||7,321,121||1.30%|
|Bnp Paribas Noms Pty Ltd||6,972,741||1.24%|
|Hsbc Custody Nominees (Australia) Limited A/C 2||6,528,750||1.16%|
|Mr Ian Fredrick Johnson||6,079,560||1.08%|
|Bosana Nominees Pty Ltd||5,881,496||1.05%|
|Ruth Karen Devney||5,626,408||1.00%|
|Nicola Jayne Rigby||4,846,220||0.86%|